



ESMO Preceptorship on Gastric Cancer

PROGRAMME

ESMO PRECEPTORSHIP

**SINGAPORE
29-30 NOVEMBER 2023**

Co-Chairs

Hanneke van Laarhoven, Netherlands
Matthew C. H. Ng, Singapore

ESMO PRECEPTORSHIP PROGRAMME

GASTRIC CANCER

Multidisciplinary management, standards of care, therapeutic targets
and future perspectives

Singapore
29-30 November 2023

CHAIRS

Hanneke van Laarhoven, Netherlands
Matthew C. H. Ng, Singapore

SPEAKERS

Irit Ben-Aharon, Israel
Tony K. H. Lim, Singapore
Brigette Ma, Hong Kong
Joanne Y. Y. Ngeow, Singapore

Sun Young Rha, South Korea
Elizabeth Smyth, United Kingdom
Jimmy B. Y. So, Singapore
Raghav Sundar, Singapore

LEARNING OBJECTIVES

- To learn the fundamental of epidemiology, aetiology, pathogenesis, molecular events, and ethnic patterns as contributing factors to heterogeneity in gastric cancer (GC)
- To understand the importance of pathology and molecular factors
- To learn about best clinical practice in the multidisciplinary management of gastric and gastro-esophageal junction (GEJ) and esophageal squamous cell cancers in the adjuvant and metastatic settings
- To learn about current best practice for endoscopic and surgical resection of localised gastric cancer
- To be able to compare the benefits of neo-adjuvant, adjuvant approaches and the value of radiotherapy in the management of localised gastro-esophageal cancers
- To learn about the management of patients after progression, in special situations, and side effects of treatments
- To learn about the advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 29 November 2023

09:30-09:40 10'	Welcome and introduction	Hanneke van Laarhoven, NL Matthew C. H. Ng, SG
09:40-11:10 90'	SESSION 1 Epidemiology, pathology and multidisciplinary management of localised gastric cancer	Chair: Matthew C. H. Ng, SG
25'	Epidemiology, pathogenesis and molecular subtypes	Brigette Ma, HK
25'	How pathology can guide treatment: HER2, MSI, PDL1, Claudin 18.2 and EBV	Tony K. H. Lim, SG
25'	Biology of peritoneal mets in gastric cancer	Raghav Sundar, SG
15'	Discussion	Faculty
11:10-11:40	Coffee break	
11:40-13:15 95'	SESSION 2 Epidemiology, pathology and multidisciplinary management of localised gastric and esophageal cancer – Part I	Chair: Elizabeth Smyth, UK
25'	A practical approach to hereditary gastric cancers	Joanne Y. Y. Ngeow, SG
25'	Advances in surgery: Endoscopic, minimally invasive, optimal nodal dissection and organ-sparing (spleen, omentum)	Jimmy B. Y. So, SG
30'	Neo- and adjuvant approaches to GC and GEJ	Matthew C. H. Ng, SG
15'	Discussion	Faculty
13:15-13:45 30'	SESSION 3 Participants clinical case discussion	Chair: Matthew C. H. Ng, SG
30'	Participants clinical case discussion (2x15') (<i>localised disease</i>)	Faculty
13:45-14:45	Lunch	
14:45-15:50 65'	SESSION 4 Epidemiology, pathology and multidisciplinary management of localised gastric and esophageal cancer – Part II	Chair: Raghav Sundar, SG
25'	Approaches to investigate heterogeneity in gastric cancer	Raghav Sundar, SG
25'	Management of gastro-esophageal cancers in young adults	Irir Ben-Aharon, IL
15'	Discussion	Faculty
15:50-16:20	Coffee break	
16:20-17:05 45'	SESSION 5 Participants clinical case discussion	Chair: Matthew C. H. Ng, SG
45'	Participants clinical case discussion (3x15') (<i>localised disease</i>)	Faculty
19:00	Networking dinner	

Thursday, 30 November 2023

09:00-10:30 90'	SESSION 6 Metastatic gastric and esophageal cancer	Chair: Sun Young Rha, KR
25'	Optimizing chemotherapy and molecularly targeted therapy	Elizabeth Smyth, UK
25'	Immunotherapy monotherapy or in combination and when best to give it	Sun Young Rha, KR
25'	Approaches to treat oligometastatic disease	Hanneke van Laarhoven, NL
15'	Discussion	Faculty
10:30-11:00 Coffee break		
11:00-12:15 75'	SESSION 7 Participants clinical case discussion	Chair: Hanneke van Laarhoven, NL
75'	Participants clinical case discussion (5x15') (<i>advanced disease</i>)	Faculty
12:15-12:20 5'	Conclusion and farewell	Hanneke van Laarhoven, NL Matthew C. H. Ng, SG
12:20-13:20 Lunch		

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion